SEC Form 4 · accession 0001213900-17-011195
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Mark Slager
Director
Period of report
Oct 31, 2017
Accepted (ET)
Nov 1, 2017 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 31, 2017 | M | 16,892 | $3.7656 | A | 1,316,328 | I | By Regals Fund LP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to buy)F2,F3 | $3.7656 | Oct 31, 2017 | M | 16,892 | D | Nov 5, 2012 | Nov 5, 2017 | Common Stock | 16,892 | 0 | I |
Explanation of responses
- F1Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein.
- F2The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
- F3The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.